Tadas Urbonas, Dalius Petrauskas, Vytautas Kiudelis, Laimas Jonaitis, Jurgita Skieceviciene, Rolandas Gedgaudas, Edita Kiudeliene, Irena Valantiene, Romanas Zykus, Greta Varkalaite, Ruta Inciuraite, Elzbieta Trapenske, Ugne Kulokiene, Paulius Jonaitis, Rima Ramonaite, Justina Velickiene, Aida Zvirbliene, Egidijus Morkunas, Irma Kuliaviene, Jolanta Sumskiene, Kestutis Adamonis, Andrius Macas, Kristina Kupcinskiene, Laura Lukosiene, Dainius Janciauskas, Lina Poskiene, Astra Vitkauskiene, Gianluca Ianiro, Antonio Gasbarrini, Gediminas Kiudelis, Juozas Kupcinskas
{"title":"粪便微生物组移植治疗复发性CDI：口服胶囊治疗的疗效和安全性。","authors":"Tadas Urbonas, Dalius Petrauskas, Vytautas Kiudelis, Laimas Jonaitis, Jurgita Skieceviciene, Rolandas Gedgaudas, Edita Kiudeliene, Irena Valantiene, Romanas Zykus, Greta Varkalaite, Ruta Inciuraite, Elzbieta Trapenske, Ugne Kulokiene, Paulius Jonaitis, Rima Ramonaite, Justina Velickiene, Aida Zvirbliene, Egidijus Morkunas, Irma Kuliaviene, Jolanta Sumskiene, Kestutis Adamonis, Andrius Macas, Kristina Kupcinskiene, Laura Lukosiene, Dainius Janciauskas, Lina Poskiene, Astra Vitkauskiene, Gianluca Ianiro, Antonio Gasbarrini, Gediminas Kiudelis, Juozas Kupcinskas","doi":"10.15403/jgld-5990","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Fecal microbiota transplantation is an effective treatment method for recurrent Clostridioides difficile infection. Widely used enteric tube and colonoscopy methods demonstrate excellent efficacy and safety results. Recent data suggest that new fecal microbiota transplantation methods using oral capsules may provide a less invasive approach. In this study, we aimed to compare primary fecal microbiota transplantation efficacy as well as short- and long-term safety of two different administration routes: oral capsules and enteric tube.</p><p><strong>Methods: </strong>This retrospective study included 60 consecutive patients who underwent fecal microbiota transplantation for recurrent Clostridioides difficile infection. Thirty participants received 50 oral capsules containing frozen material for a single day and 30 patients received fecal microbiota transplantation via nasoenteric tube. All patients received standard treatment with oral vancomycin 500 mg q.i.d. for at least five days before the procedure. After intervention, patients were followed up for at least six months. Data on Clostridioides difficile infection recurrences and health status were collected and analyzed.</p><p><strong>Results: </strong>The oral capsules group consisted of 30 patients. Among them, 22 (73.3%) participants experienced resolution of symptoms after a single fecal microbiota transplantation, while eight (26.7%) patients developed recurrent diarrhea within eight weeks. The other 30 patients received treatment via nasoenteric tube. Among them, 24 (80%) patients were cured after a single fecal microbiota transplantation, while six (20%) experienced recurrent disease within eight weeks. The primary efficacy did not show significant differences between the two groups (p=0.85). Throughout the follow-up period, no serious adverse events or fecal microbiota transplantation related deaths were reported in both groups.</p><p><strong>Conclusions: </strong>Fecal microbiota transplantation with frozen oral capsules is a safe, less invasive method with comparable efficacy to nasoenteric administration route.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"199-204"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules.\",\"authors\":\"Tadas Urbonas, Dalius Petrauskas, Vytautas Kiudelis, Laimas Jonaitis, Jurgita Skieceviciene, Rolandas Gedgaudas, Edita Kiudeliene, Irena Valantiene, Romanas Zykus, Greta Varkalaite, Ruta Inciuraite, Elzbieta Trapenske, Ugne Kulokiene, Paulius Jonaitis, Rima Ramonaite, Justina Velickiene, Aida Zvirbliene, Egidijus Morkunas, Irma Kuliaviene, Jolanta Sumskiene, Kestutis Adamonis, Andrius Macas, Kristina Kupcinskiene, Laura Lukosiene, Dainius Janciauskas, Lina Poskiene, Astra Vitkauskiene, Gianluca Ianiro, Antonio Gasbarrini, Gediminas Kiudelis, Juozas Kupcinskas\",\"doi\":\"10.15403/jgld-5990\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Fecal microbiota transplantation is an effective treatment method for recurrent Clostridioides difficile infection. Widely used enteric tube and colonoscopy methods demonstrate excellent efficacy and safety results. Recent data suggest that new fecal microbiota transplantation methods using oral capsules may provide a less invasive approach. In this study, we aimed to compare primary fecal microbiota transplantation efficacy as well as short- and long-term safety of two different administration routes: oral capsules and enteric tube.</p><p><strong>Methods: </strong>This retrospective study included 60 consecutive patients who underwent fecal microbiota transplantation for recurrent Clostridioides difficile infection. Thirty participants received 50 oral capsules containing frozen material for a single day and 30 patients received fecal microbiota transplantation via nasoenteric tube. All patients received standard treatment with oral vancomycin 500 mg q.i.d. for at least five days before the procedure. After intervention, patients were followed up for at least six months. Data on Clostridioides difficile infection recurrences and health status were collected and analyzed.</p><p><strong>Results: </strong>The oral capsules group consisted of 30 patients. Among them, 22 (73.3%) participants experienced resolution of symptoms after a single fecal microbiota transplantation, while eight (26.7%) patients developed recurrent diarrhea within eight weeks. The other 30 patients received treatment via nasoenteric tube. Among them, 24 (80%) patients were cured after a single fecal microbiota transplantation, while six (20%) experienced recurrent disease within eight weeks. The primary efficacy did not show significant differences between the two groups (p=0.85). Throughout the follow-up period, no serious adverse events or fecal microbiota transplantation related deaths were reported in both groups.</p><p><strong>Conclusions: </strong>Fecal microbiota transplantation with frozen oral capsules is a safe, less invasive method with comparable efficacy to nasoenteric administration route.</p>\",\"PeriodicalId\":94081,\"journal\":{\"name\":\"Journal of gastrointestinal and liver diseases : JGLD\",\"volume\":\"34 2\",\"pages\":\"199-204\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of gastrointestinal and liver diseases : JGLD\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15403/jgld-5990\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastrointestinal and liver diseases : JGLD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15403/jgld-5990","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules.
Background and aims: Fecal microbiota transplantation is an effective treatment method for recurrent Clostridioides difficile infection. Widely used enteric tube and colonoscopy methods demonstrate excellent efficacy and safety results. Recent data suggest that new fecal microbiota transplantation methods using oral capsules may provide a less invasive approach. In this study, we aimed to compare primary fecal microbiota transplantation efficacy as well as short- and long-term safety of two different administration routes: oral capsules and enteric tube.
Methods: This retrospective study included 60 consecutive patients who underwent fecal microbiota transplantation for recurrent Clostridioides difficile infection. Thirty participants received 50 oral capsules containing frozen material for a single day and 30 patients received fecal microbiota transplantation via nasoenteric tube. All patients received standard treatment with oral vancomycin 500 mg q.i.d. for at least five days before the procedure. After intervention, patients were followed up for at least six months. Data on Clostridioides difficile infection recurrences and health status were collected and analyzed.
Results: The oral capsules group consisted of 30 patients. Among them, 22 (73.3%) participants experienced resolution of symptoms after a single fecal microbiota transplantation, while eight (26.7%) patients developed recurrent diarrhea within eight weeks. The other 30 patients received treatment via nasoenteric tube. Among them, 24 (80%) patients were cured after a single fecal microbiota transplantation, while six (20%) experienced recurrent disease within eight weeks. The primary efficacy did not show significant differences between the two groups (p=0.85). Throughout the follow-up period, no serious adverse events or fecal microbiota transplantation related deaths were reported in both groups.
Conclusions: Fecal microbiota transplantation with frozen oral capsules is a safe, less invasive method with comparable efficacy to nasoenteric administration route.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
